- Home
- DTIL vs CUPR Comparison
DTIL vs CUPR Comparison
Compare DTIL & CUPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- CUPR
- Stock Information
- Founded
- DTIL 2006
- CUPR 2019
- Country
- DTIL United States
- CUPR Singapore
- Employees
- DTIL N/A
- CUPR N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- CUPR
- Sector
- DTIL Health Care
- CUPR
- Exchange
- DTIL Nasdaq
- CUPR NYSE
- Market Cap
- DTIL 51.6M
- CUPR 43.2M
- IPO Year
- DTIL 2019
- CUPR 2025
- Fundamental
- Price
- DTIL $4.49
- CUPR $7.30
- Analyst Decision
- DTIL Strong Buy
- CUPR
- Analyst Count
- DTIL 2
- CUPR 0
- Target Price
- DTIL $47.00
- CUPR N/A
- AVG Volume (30 Days)
- DTIL 546.0K
- CUPR 300.3K
- Earning Date
- DTIL 07-31-2025
- CUPR 01-01-0001
- Dividend Yield
- DTIL N/A
- CUPR N/A
- EPS Growth
- DTIL N/A
- CUPR N/A
- EPS
- DTIL N/A
- CUPR N/A
- Revenue
- DTIL $51,141,000.00
- CUPR $35,406.00
- Revenue This Year
- DTIL N/A
- CUPR N/A
- Revenue Next Year
- DTIL $30.20
- CUPR N/A
- P/E Ratio
- DTIL N/A
- CUPR N/A
- Revenue Growth
- DTIL N/A
- CUPR N/A
- 52 Week Low
- DTIL $3.61
- CUPR $3.51
- 52 Week High
- DTIL $11.09
- CUPR $7.46
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- CUPR N/A
- Support Level
- DTIL $4.08
- CUPR N/A
- Resistance Level
- DTIL $4.38
- CUPR N/A
- Average True Range (ATR)
- DTIL 0.28
- CUPR 0.00
- MACD
- DTIL 0.05
- CUPR 0.00
- Stochastic Oscillator
- DTIL 85.26
- CUPR 0.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.